Aegerion Pharmaceuticals (NASDAQ: AEGR) is up 30%, thanks to a presentation at the Bank of America Merrill Lynch 2013 Healthcare Conference. Analysts have literally rushed out and threw upgrades at the stock after the company announced a price hike for HoFH drug Juxtapid.
In this video, health-care analyst David Williamson discusses what these events mean for investors in Aegerion, and also for its competitors.
Another health-care topic that investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.